Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
Subtype terms (1)
More specific conditions that are subtypes of Ventricular Dysfunction, Left in the MeSH hierarchy.
- Takotsubo Cardiomyopathy
9 drugs (7 approved, 2 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (13)
Phase 3 trials (11)
Phase 2 trials (5)
Phase 1 trials (2)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (20)
- Forest Laboratories
- Gilead Sciences
- AstraZeneca
- Alexion
- National Center for Research Resources (NCRR)
- University of Arizona
- Boston University
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Danderyds Hospital
- Yonsei University
- Tel Aviv University
- University of Ulsan
- Icahn School of Medicine at Mount Sinai
- Technion University
- H2O Clinical LLC
- University of Texas, Arlington
- Government of Taiwan
- IQVIA
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (15)
- Servier
- Biosyn
- Mallinckrodt
- Menarini Group
- University of London
- Duke University
- RWTH Aachen University
- University of Cape Town
- University of Limoges
- Momentum Research, Inc.
- University of Barcelona
- University and Emergency Hospital Bucharest, Romania
- European Union
- University Hospital, Tours
- Universidad Carlos III Madrid
Organization Involved with Phase 2 Indications (25)
- Actelion
- Daiichi Sankyo
- Scios
- Amgen
- Astellas
- Bayer
- Cytokinetics
- Quantum Genomics SA
- The EMMES Corporation
- The Heartbeat Trust
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Johns Hopkins University
- McMaster University
- University of Miami
- Mayo Clinic
- University of Toulouse
- Cardiovascular Cell Therapy Research Network
- Sorbonne University
- University of Texas at Houston
- University of Nantes
- CV Ventures
- Government of France
- National University of Ireland
- St Vincent's University Hospital, Ireland
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (3)